Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

The Food and Drug Administration has approved the world’s first medicine based on CRISPR gene-editing technology, a ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034, ...

CRISPR Therapeutics has not performed well in the past year and a half since hitting that milestone. Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

NRI PULSE STAFF REPORT Indian American physician-scientist and business executive Reshma Kewalramani, the CEO of Vertex ...

Learn more about whether CRISPR Therapeutics AG or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Adria Cimino has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Vertex Pharmaceuticals (NASDAQ ... what they believe are the 10 best stocks to buy right now. Learn More » CRISPR Therapeutics (NASDAQ: CRSP) is a biotech that generally tackles specialties ...

Vertex Pharmaceuticals (NASDAQ ... including one approved early this year. CRISPR Therapeutics (NASDAQ: CRSP) is a biotech that generally tackles specialties different from those of Vertex ...